Andrew Dudum Sells 125,335 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CEO Andrew Dudum sold 125,335 shares of the business's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $49.54, for a total transaction of $6,209,095.90. Following the transaction, the chief executive officer owned 92,313 shares in the company, valued at $4,573,186.02. This trade represents a 57.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Wednesday, July 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $50.25, for a total value of $2,388,583.50.
• On Wednesday, July 16th, Andrew Dudum sold 2,792 shares of Hims & Hers Health stock. The stock was sold at an average price of $50.58, for a total value of $141,219.36.
• On Tuesday, June 17th, Andrew Dudum sold 65,110 shares of Hims & Hers Health stock. The stock was sold at an average price of $59.22, for a total transaction of $3,855,814.20.
• On Monday, June 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $56.51, for a total transaction of $2,686,146.34.
• On Monday, June 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $56.76, for a total transaction of $7,272,488.52.
• On Friday, May 16th, Andrew Dudum sold 47,534 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.25, for a total transaction of $2,768,855.50.
• On Friday, May 16th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $58.40, for a total value of $7,482,616.80.
• On Tuesday, April 29th, Andrew Dudum sold 50,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.39, for a total value of $1,819,500.00.

Hims & Hers Health Stock Up 0.3%

Shares of Hims & Hers Health stock traded up $0.18 during trading on Friday, reaching $57.50. The company's stock had a trading volume of 46,302,225 shares, compared to its average volume of 30,801,588. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The company has a 50-day simple moving average of $53.15 and a two-hundred day simple moving average of $42.88. The company has a market cap of $12.87 billion, a price-to-earnings ratio of 83.33, a P/E/G ratio of 2.13 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same quarter last year, the company earned $0.05 earnings per share. The company's quarterly revenue was up 110.7% on a year-over-year basis. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their price target for the stock from $44.00 to $30.00 in a research report on Tuesday, April 29th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Bank of America lifted their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health presently has an average rating of "Hold" and a consensus target price of $39.83.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Webster Bank N. A. boosted its position in Hims & Hers Health by 229.1% during the second quarter. Webster Bank N. A. now owns 905 shares of the company's stock worth $45,000 after purchasing an additional 630 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health during the 1st quarter valued at approximately $30,000. Parallel Advisors LLC grew its stake in Hims & Hers Health by 175.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,155 shares of the company's stock valued at $58,000 after acquiring an additional 735 shares during the period. UMB Bank n.a. increased its holdings in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after acquiring an additional 933 shares in the last quarter. Finally, AdvisorNet Financial Inc raised its position in Hims & Hers Health by 127.1% during the second quarter. AdvisorNet Financial Inc now owns 1,340 shares of the company's stock worth $67,000 after acquiring an additional 750 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.